TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Phase 3 study of obicetrapib, a cholesterol-lowering drug developed by NewAmsterdam Pharma, found lower blood levels of the Alzheimer’s biomarker pTau-217 in a subgroup of participants carrying the ApoE4 risk gene. That result does not show the drug prevents or treats Alzheimer’s. A separate Phase 2b trial is now testing biomarker effects in people with Alzheimer’s hallmarks but no symptoms.
Obicetrapib, an investigational cholesterol-lowering drug, reduced blood levels of the Alzheimer’s biomarker pTau-217 among a subgroup of participants carrying the ApoE4 risk gene in a Phase 3 study, according to a report by Being Patient. The finding is a signal for further research, not evidence that lowering cholesterol can prevent or treat Alzheimer’s; NewAmsterdam Pharma has begun a Phase 2b trial to investigate the question further.
The Phase 3 study tested obicetrapib, a CETP inhibitor that works by limiting the transfer of cholesterol into LDL, in people with heart disease or a genetic form of high cholesterol. In a subgroup of 1,727 ApoE4 carriers, researchers reported lower blood pTau-217 levels. The report describes pTau-217 as a biomarker used to help diagnose Alzheimer’s in people who have cognitive impairment.
The biomarker result does not establish a change in participants’ memory, thinking, dementia risk or disease progression. Mayo Clinic neurologist Dr. David Knopman told Being Patient that what the finding means is unknown, though it could support testing the drug’s effects on cognition. NewAmsterdam Pharma has enrolled the first participant in a Phase 2b Alzheimer’s trial, which will examine whether a year of treatment changes biomarkers in people with Alzheimer’s hallmarks but no symptoms.
The broader evidence on cholesterol drugs and dementia is mixed. A Danish electronic health-record study of more than 130,000 people with Type 2 diabetes, published in Lancet Regional Health Europe, found that people who started statins early had a 15% lower dementia risk over a decade; those who started later had a 10% lower risk. Those are observational associations, not proof that statins caused the difference. A randomized trial in healthy adults over 70 did not find a dementia-prevention effect, while two earlier major statin trials did not show treatment of cognitive decline.
A Biomarker Signal, Not a Treatment Result
The obicetrapib finding could help shape a new research question: whether a cholesterol drug that affects blood biomarkers can also change Alzheimer’s biology or cognitive outcomes. That matters because earlier statin trials did not show that these drugs treated cognitive decline, and the evidence for preventing dementia remains unsettled.
For patients and families, the distinction is practical. A change in pTau-217 in blood is not the same as evidence that someone is less likely to develop dementia or will retain memory and independence for longer. The new trial must test whether any biomarker change is meaningful for people, rather than assuming it signals a clinical benefit.
The results may also be relevant to people with ApoE4, a gene associated with increased Alzheimer’s and cardiovascular risk. But the reported subgroup finding cannot establish that the drug would benefit all carriers, people with other risk profiles, or those already experiencing symptoms. The trial’s results will be needed before drawing conclusions about possible prevention or treatment.
cholesterol-lowering supplements for brain health
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Why Cholesterol Research Returned
Cholesterol circulates through the body in particles including LDL and HDL. The report notes that cholesterol in the blood does not enter the brain because the molecule is too large. Researchers are nevertheless studying whether disruptions in the brain’s own cholesterol metabolism contribute to Alzheimer’s. ApoE4 affects cholesterol processing as well as Alzheimer’s and cardiovascular risk, making it relevant to this line of research.
Statins are commonly used to lower LDL and reduce cardiovascular risk, including for many people with Type 2 diabetes. But they do not readily reach the brain, according to the report, which is one reason some researchers doubt they would alter cholesterol metabolism there. Earlier randomized trials did not show that statins treated cognitive decline, and a trial in healthy adults over 70 did not find a dementia-prevention effect.
The Danish study offers a different kind of evidence. Its long follow-up—nearly 20 years for some participants—makes it possible to examine dementia diagnoses over time, but health-record research cannot fully account for differences between people who do and do not take statins. The report cites the possibility that statin users may also be more medically informed or more likely to follow healthy behaviors.
““It’s unknown” what the biomarker result means.”
— Dr. David Knopman, neurologist at the Mayo Clinic
statin medications for dementia prevention
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What the Biomarker Cannot Show
The reported Phase 3 subgroup result does not show whether obicetrapib changes cognition, prevents Alzheimer’s, or slows disease in people who already have symptoms. The source report provides no clinical-outcome result from that study and does not establish why pTau-217 levels changed or whether the difference is clinically meaningful.
It is also unclear how the Phase 2b trial is designed beyond its stated one-year treatment period and enrollment of people with disease hallmarks but no symptoms. The report does not give the trial’s planned enrollment, expected completion date, detailed outcome measures or results. Until findings are available, the drug should not be described as an Alzheimer’s prevention or treatment.
The statin evidence also has limits in both directions. Observational associations cannot prove cause and effect, while a negative result in one older-adult trial does not answer every question about timing, duration or different populations. The report says long-term dementia-prevention trials of statins may be difficult to fund, leaving important questions unresolved.
blood biomarker testing kits for Alzheimer’s
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Results From the Phase 2b Trial
The next reported milestone is the Phase 2b trial of obicetrapib, which will test whether a year of treatment changes Alzheimer’s biomarkers in people who have disease hallmarks but no symptoms. The first participant has been enrolled, according to Being Patient. The report does not state when results are expected.
Researchers and readers will need to distinguish biomarker outcomes from clinical ones. A later study showing changes in memory, thinking or disease progression would address a different question from whether blood pTau-217 moves. For now, the available finding supports further investigation, while the effect of cholesterol-lowering treatment on Alzheimer’s risk and symptoms remains unproven.
As an affiliate, we earn on qualifying purchases.
Key Questions
Does obicetrapib prevent Alzheimer’s?
That has not been shown. The reported Phase 3 finding was a reduction in blood pTau-217 in a subgroup of ApoE4 carriers; it did not establish lower dementia risk.
Does lowering cholesterol with statins treat Alzheimer’s?
Major randomized trials described in the report did not show that statins treated cognitive decline. The available evidence does not establish statins as an Alzheimer’s treatment.
What does the pTau-217 result mean?
It is a change in a blood biomarker used to help diagnose Alzheimer’s in people with cognitive impairment. It does not by itself show that memory, thinking, or disease progression improved.
What is the new obicetrapib trial testing?
The Phase 2b trial is testing whether a year of obicetrapib treatment changes Alzheimer’s biomarkers in people with disease hallmarks but no symptoms. The report does not provide a results timeline or detailed trial outcomes.
Do the statin studies prove that statins prevent dementia?
No. A Danish observational study found lower dementia risk among people who started statins earlier, but it cannot prove the medication caused the difference. A randomized trial in healthy adults over 70 did not find a prevention effect.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
